Loading
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
Regular session
$0.1824
+$0.0043 · +2.41%
Regular session · ET · Market data may be delayed.
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
Day range
Current $0.1824
52-week range
Current $0.1824
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
41
Fair Value
Sentiment
59
Mixed
Risk
63
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
Day range
Current $0.1824
52-week range
Current $0.1824
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 7.5K USD | 686K USD | 284K USD | 110K USD |
| Gross profit | — | 7.5K USD | 686K USD | 284K USD | 110K USD |
| Research and development | 4.84M USD | 4.72M USD | 3.64M USD | 6.1M USD | 5.38M USD |
| Selling, general, and administrative | 6.13M USD | 6.27M USD | 4.49M USD | 3.64M USD | 3.95M USD |
| Operating expenses | 10.97M USD | 10.99M USD | 8.14M USD | 9.74M USD | 9.33M USD |
| Interest income | 70.21K USD | 122.55K USD | 1.58K USD | 4.82K USD | 8.76K USD |
| Interest expense | 7.59K USD | 12.16K USD | 167.73K USD | 251.89K USD | 66.97K USD |
| Depreciation and amortization | 453.14K USD | 448.24K USD | 425.55K USD | 405.98K USD | 84.77K USD |
| Operating income | −10.97M USD | −10.99M USD | −7.45M USD | −9.45M USD | −9.22M USD |
| Net income | −10.96M USD | −8.97M USD | −11.28M USD | −10.68M USD | −8.94M USD |
Company facts updated Sep 10, 2026.
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 21, 2025 | 6.66:1 | — | — |
Stock split | Jul 1, 2024 | 1:30 | — | — |
Effective Aug 21, 2025
6.66:1
Effective Jul 1, 2024
1:30
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
